50th week of 2021 patent applcation highlights part 7 |
Patent application number | Title | Published |
20210386607 | PROTECTIVE SHIELD SYSTEM - Methods, apparatus, and systems for reducing transmission of aerosol droplets in a medical or dental procedure are described. One protective shield system includes a base plate, a shield having at least one transparent section, and a pipe or conduit comprising a plurality of holes thereon. The shield is configured to be removably attached to the base plate to allow attachment of the shield to the base plate prior to the medical or dental procedure and removal of the shield from the base plate after the medical or dental procedure. The pipe or conduit is positioned adjacent to an inner surface of the shield and on at least part of a perimeter of the shield. The pipe includes an end that is configured to connect to a suction system to enable removal of the aerosolized particles from below the shield during the medical or dental procedure. | 2021-12-16 |
20210386608 | Low Vibration Delivery System - Improved low vibrational delivery system, suitable for individual to lie or sit upon and receive vibration. Multiple layers of vibrational attenuation iterative internally within design facilitate the optimized delivery, especially with regards to low vibrations. Key methodologies with regards to structural stability and the functional, unimpeded localization of resonators completes the novel, coherent design for optimized vibrational delivery which this invention embodies. | 2021-12-16 |
20210386609 | Triangular Prism-Shaped Body Therapeutic Device - A therapeutic system may include a triangular prism-shaped body, the triangular prism-shaped body including a first rectangle plane; a second triangular plane placed at a 90° angle relative to a first side of the first plane; a third plane rectangular placed at a 30° angle relative to a second side of the first plane; a fourth triangular plane placed at a 90° angle relative to a third side of the first plan; and a fifth rectangular plane place at a 60° angle relative to a fourth side of the first plane; a heel placement depression formed in the first rectangle plane; and a foot placement identifier formed on the third rectangular plane originating at the joint of the first rectangular plane and third rectangular plane and extending into the third rectangular plane. | 2021-12-16 |
20210386610 | HIP JOINT LINK APPRATUS - An embodiment of the present invention provides a hip joint link apparatus including: an upper body link fixed to an upper body of a wearable robot, and a hip joint jointer linking a thigh link linked to a thigh of the wearable robot, wherein the hip joint jointer has a four-revolute joint structure including a plurality of revolute joints and a plurality of links; an arbitrary input moment to the hip joint jointer is changed to an output moment in a predetermined direction based on a state of being transmitted to the plurality of links through the plurality of revolute joints; and the hip joint jointer assists a flexion moment, an extension moment, an abduction moment, and an adduction moment. | 2021-12-16 |
20210386611 | CLOUD-BASED CONTROL SYSTEM AND METHOD ENABLING INTERACTIVE CLINICAL CARE USING A POWERED MOBILITY ASSISTANCE DEVICE - A cloud-based control method and related system implements enhanced control of a network of mobility assistance devices. The control method implemented by the cloud-based system includes the steps of: monitoring performance of the mobility assistance device with a device user electronic device; based on said monitoring, transmitting raw data regarding performance of the mobility assistance device from the device user electronic device to a remote datacenter; processing the raw data with the remote datacenter to generate processed user data that is suitable for use by a data user; transmitting the processed user data to a data user electronic device that is accessible to the data user, wherein the data user generates user actions data for optimizing performance of the mobility assistance device; transmitting the user actions data from a data user electronic device to the remote datacenter; processing the user actions data with the remote datacenter to generate processed control data for optimizing performance of the mobility assistance device; and transmitting the processed control data to a device user electronic device, wherein the processed control data controls performance of the mobility assistance device to optimize performance of the mobility assistance device. | 2021-12-16 |
20210386612 | WALKER STEP - A walker that includes a first frame having first and second legs, a second frame having first and second legs, one or more support bars connecting the first leg of the first frame to the first leg of the second frame; and a foldable or stowable foot rest. | 2021-12-16 |
20210386613 | THERAPEUTIC APPARATUS AND METHOD FOR EFFECTING AUTOMATED PARALLEL MOBILIZATION OF A MUSCLE OR TENDON - A therapeutic apparatus and a method for providing parallel mobilization treatment of a muscle or a tendon in a limb utilizing the therapeutic apparatus. | 2021-12-16 |
20210386614 | ELECTRO-ACTUATABLE COMPRESSION GARMENTS WITH SHAPE MEMORY ELEMENTS - A compression garment having one or more flex frames that can be shortened or lengthened to apply or release a compressive force to the limb or other anatomical feature of a user. The compression garment can have a wire made of shape memory material (shape memory alloy). A controller of the compression garment can supply an electrical input to the wire, generating heat that can cause the wire to contract such that the flex frame deflects to a shorter length to apply a compressive force to the limb or other anatomical feature of the user. The one or more flex frames can be contracted in unison or in sequence to direct the flow of bodily fluids in the limb or other anatomical feature of the user. | 2021-12-16 |
20210386615 | WEARABLE HEALTH MANAGEMENT SYSTEM - A wearable health management system includes a flexible member configured to be worn on an affected area by a patient. At least one actuator is operably coupled to the flexible member. The at least one actuator is configured to be adjusted between a deployed state and a non-deployed state. At least one of a photoplethysmogram sensor and a bioimpedance sensor is coupled to the flexible member to obtain one or more health metrics from the patient. A controller is in communication with the at least one actuator. The controller is configured to adjust the at least one actuator to the deployed state to provide a selected pressure to the affected area. | 2021-12-16 |
20210386616 | BODY SHAPING STICK - The present disclosure discloses a body shaping stick, and relates to the field of medical health-care instruments. The body shaping stick includes a stick body ( | 2021-12-16 |
20210386617 | Meibomian Gland Roller - A Meibomian Gland Roller system allows for self-administered the treatment for a leading cause of dry eyes, namely, tear film oil deficiency. The system combines an effective and safe technique to combine mechanical rolling pressure with heat for meibomian gland drainage. The rolling action of the roller cylinder combined with the roller head to increase effectiveness in empting inspis sated meibomian glands. The roller allows the patient to safely start the application of the pressure at the bottom of the glands and effectively roll open clogged oil glands. The washable roller keeps the head clean for long term use. A preheated eye-shaped soft gel pad can prepare the lids before the roller tip is applied by heating and softening the meibomian gland contents, allowing the roller to have a more effective action to induce mechanical extraction of the gland content. | 2021-12-16 |
20210386618 | VIBRATORY POOL NOODLE - A vibratory pool noodle for supporting a user to remain afloat in water and also provides vibration massage to different body parts of the user. The vibratory pool noodle includes an outer core made from a buoyant material, the outer core is hollow, the outer core of a prolonged tubular shape having a proximal end and a distal end; an inner core encased in the outer core, the inner core made of a pliable material; and a vibration motor encased in the outer core, the vibration motor impart vibrations to the vibratory pool noodle which in turn can transfer the vibrations to the one or more body parts of the user in contact with the vibratory pool noodle for massaging the one or more body parts. | 2021-12-16 |
20210386619 | CHEST COMPRESSION RAIL SYSTEM AND METHODS FOR USING SAME - A removeable and easily attachable/detachable rail system for use with chest compression devices and portable patient carrier boards. The rail system can include an elongated grooved structure providing multiple points of attachment for a chest compression device. The elongated grooved structure is removably affixed to the carrier board using one or more clamp mechanisms adapted to engage a side panel or hand hole of the board. The rail system allows first responders the ability to quickly and efficiently provide cardiopulmonary resuscitation assistance to a patient, while allowing for faster patient transport. | 2021-12-16 |
20210386620 | FOLDING SAUNA ENCLOSURE - A portable, personal therapy chamber for provision of radiation therapy. The therapy chamber includes a pair of telescopically positionable units that are lightweight and easily portable by a single user. The therapy chamber is configured for use by a single person lying generally prone on a surface. The units are formed from a plurality of pivotably coupled panels that are foldable in a first direction to a rolled up, tube-like storage configuration and unfoldable in a second direction to an arched formation or use configuration. The units, in the use configuration, are disposed to overlie the user and include a plurality of emitters that direct infrared energy toward the user's body. | 2021-12-16 |
20210386621 | PROTECTIVE LOCKING SYSTEMS FOR USE WITH VIALS - Protective locking systems for source vials which helps prevent mishandling of liquid medication to be removed from source vials and used in an injection device, such as a wearable injection device or a syringe. The protective locking systems include at least a key, a locking cap and a slide guard, each of which includes an opening sized at least large enough to receive a needle therethrough. | 2021-12-16 |
20210386622 | FLUID COUPLINGS - Some fluid coupling devices described herein are configured for use in fluid systems for purposes of providing a sterile connection for drug delivery. In some embodiments, the fluid coupling devices can be implemented as multi-use, sterile fluid coupling devices that are configured to reduce the likelihood of fluid spillage when being disconnected. | 2021-12-16 |
20210386623 | PORTABLE APPARATUS AND METHOD FOR STERILE PHARMACEUTICAL MANUFACTURING - A pharmaceutical mobile machine to produce a sterile dosage pharmaceutical form from non-sterile or sterile ingredients amenable for human dosing and administration, The pharmaceutical machine includes an ingredient combiner module including a mixer to mix active and inactive pharmaceutical ingredients and a transfer conduit to transfer the mixed ingredients from the ingredient combiner module. A final product module is operatively connected to the transfer conduit to receive the mixed ingredients from the ingredient combiner module. The final product module includes filling equipment to fill one or more containers to produce the sterile dosage pharmaceutical form. An environment module includes an air purifying system having an outlet operatively connected to the final product module, wherein the air purifying system provides purified air to the final product module through the outlet. | 2021-12-16 |
20210386624 | MANUFACTURING DEVICE FOR GELATIN CAPSULE - Provided is a manufacturing device for a gelatin capsule structured to include a pair of medicinal solution supply units configured to supply medicinal solutions being filled in the capsule while adopting most of structures of an existing manufacturing device for a soft capsule. The device is capable of manufacturing capsules where one capsule is charged with medicinal solutions different from each other, or is capable of increasing productivity compared to the existing manufacturing device. | 2021-12-16 |
20210386625 | STORAGE CONTAINER FOR A STORAGE AND DISPENSING STATION - A storage container for a storage and dispensing station for small piece goods, in particular drugs or dietary supplement products, is provided. The storage container includes a housing with an on the inside circular cylindrical section, a separating device arranged in the on the inside circular cylindrical section including a base body and multiple channels, the channels being open to the outer periphery of the separating device and each channel having a peripheral wall and two radial walls, and a retainer. At least one radial wall and/or the peripheral wall includes a depression and/or an elevation to reduce a contact area between a small piece good and the channel wall, the shape and size of the depression/elevation being selected in such a way that an electrostatic attraction between the small piece good and the channel wall is reduced. | 2021-12-16 |
20210386626 | HANDHELD MEDICAMENT DISPENSER - The present invention relates to a hand-held medicament dispenser. The invention further relates to a hand-held medicament dispenser with an exchangeable cartridge contained therein. The invention further relates to uses of the medicament dispenser for counting and dispensing solid medicinal units. | 2021-12-16 |
20210386627 | SECURE DEVICE FOR COUNTING AND DISPENSING OBJECTS - A device for counting and dispensing objects, including two elements. A first element includes a conduit for dispensing the objects to be counted and dispensed, and a second element cooperates with the first element to form two obturators which define, in the dispensing conduit a chamber suitable for containing a predetermined number of said objects. | 2021-12-16 |
20210386628 | MEDICINE DISPENSING DEVICE AND METHOD FOR DISPENDING MEDICINE - Disclosed is a medicine dispensing device and a method for dispensing medicine, wherein the medicine dispensing device includes a tray and a drop plate below the tray in a drop direction, wherein the drop plate is slidable relative to the tray between a hold position and a drop position, wherein the medicine dispensing device further includes one or more retaining members for retaining the drop plate relative to the tray in the drop direction when the drop plate is in a dispensing path, wherein the drop plate is slidable in a release direction into a release position outside of the dispensing path, wherein the one or more retaining members are arranged for releasing the drop plate from the tray in the release position. | 2021-12-16 |
20210386629 | AUTOMATED MEDICATION DISPOSAL MESSAGING SYSTEM - Techniques are described for automated medication disposal messaging. One method includes receiving information associated with a prescription order of a user account. In some cases, the information associated with the prescription order includes a medication identifier, medication dosage indication, and medication quantity. The method may include calculating a run out date corresponding to the target medication with the disposal guideline based on the medication dosage indication and the medication quantity. The method may also include communicating a disposal notification for the target medication based on the run out date. | 2021-12-16 |
20210386630 | ULTRAVIOLET PROTECTION PATCH AND APPLICATION METHOD THEREOF - An ultraviolet protection patch is provided. An ultraviolet protection patch, according to one embodiment of the present invention, is implemented by comprising: an ultraviolet protection layer including a support component and an ultraviolet protection agent; and a first shape-retaining layer which is a fiber web provided on one surface of the ultraviolet protection layer. According to this, as the ultraviolet protection patch comprises the ultraviolet protection layer and the shape-retaining layer which have predetermined properties, an ultraviolet protection material does not directly contact the skin, and thus skin trouble, irritation, and white cast do not occur, and as the patch is excellent in elasticity, the patch has excellent stiffness without inhibiting movement of a site to which the patch is adhered or peeling off even by physical stimuli, and the ultraviolet protection layer and the shape-retaining layer have a predetermined basis weight relationship, thereby having excellent transparency, and thus, there is an effect of not reducing visibility of the site to which the patch is adhered when the patch is adhered to the skin. | 2021-12-16 |
20210386631 | Method of Dispersing Hydrophobic Substances in Aqueous Cleansing System - This disclosure relates to a method for making a dispersion, comprising preparing an aqueous phase comprising water and a surfactant; combining a hydrophobic substance and a plurality of particles comprising cellulose to form a concentrate; and mixing the aqueous phase and concentrate to provide a dispersion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 2021-12-16 |
20210386632 | EXTERNAL PREPARATION - An external preparation containing the following component (A) and component (B). Component (A): ionic polymer particles containing structural units derived from (a) one or more hydrophobic monomers selected from the group consisting of styrene and a derivative thereof, a vinyl ester, and a hydrophobic acrylic monomer, and (b) an ionic hydrophilic monomer or a salt thereof, wherein the ratio by mass of (a) to (b), (a)/(b) is 99.5/0.5 to 80/20, and the ionic polymer particles have a glass transition temperature of higher than 5° C. and 120° C. or lower. Component (B): one or more compounds selected from the group consisting of a phenoxyethanol (B1), a 2-ethylhexyl paramethoxycinnamate (B2), a benzyl alcohol (B3), a sorbitol (B4), a specific oxyalkylene derivative (B5), a polyoxyalkylene alkyl glucoside (BG), an oleic acid (B7), an alkyl benzoate (B8), a xylitol (B9), a 2-ethylhexyl (RS)-2-cyano-3,3-diphenylprop-2-enoate (B10), and a methylphenylpolysiloxane (B11). | 2021-12-16 |
20210386633 | Rinseable Multi-Phase Compositions - A multi-phase oral composition with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier, which is rinseable from a surface and/or has a high water dispersibility. A jammed oil-in-water composition with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier, which is rinseable from a surface and/or has a high water dispersibility. Methods of using disclosed compositions for active agent delivery. | 2021-12-16 |
20210386634 | POROUS COMPOSITE POWDER FOR ADSORPTION OF FINE DUST AND METHOD FOR MANUFACTURING THE SAME - The present disclosure provides porous composite powder which includes biodegradable polymer particles with a porous structure having positive charges dispersed uniformly thereon and further includes inorganic particles. The porous composite powder adsorbs and removes fine particulate matter remaining in the skin and skin pores effectively through ionic bonding, while maintaining a spherical shape. The present disclosure also provides a method for preparing porous composite powder for adsorption of fine dust including particles forming a composite homogeneously, while maintaining a spherical shape, through a single process. | 2021-12-16 |
20210386635 | COSMETIC COMPOSITIONS CONTAINING QUINONES AND THEIR TOPICAL USE ON SKIN AND HAIR - Described are compositions containing quinones that show activity in enhance DNA repair and/or prevent damage to DNA and/or upregulate genes associated with wound healing. The quinones are thymoquinone, lapachol, myrtucommulone C, or mixtures thereof, and can be formulated into cosmetic compositions for topical administration to a subject in need thereof. The cosmetic compositions can also include sunscreens, surfactants, sunless tanning agents, desquamation agents, antiperspirants, colorants, preservatives and mixtures; and a cosmetically acceptable carrier. The compositions should find use in methods for treating the signs of ageing in mammals, dermatitis and wound healing via topical application to a site in need thereof, such as the skin or hair of the mammals or a wound site. | 2021-12-16 |
20210386636 | Composition for Enhancing Hair Fiber Properties - Described herein is a hair care composition including from about 0.01% to about 20% of a lipid being one or more unsaturated fatty materials chosen from unsaturated fatty acids, unsaturated fatty alcohols, and mixtures thereof. The unsaturated fatty material has a Log P of less than 8. The hair care composition also includes from about 0.01% to about 10% of a fatty acid monoester of a polyol, a saturated fatty alcohol, an ester of a saturated fatty alcohol, and mixtures thereof. The molecule of the fatty acid component of the fatty acid monoester includes a linear or a branched carbon chain with 10 to 22 carbon atoms. The fatty acid monoester of a polyol has a log P of less than 8. The molecule of the fatty alcohol includes a linear or branched carbon chain with 8 to 22 carbon atoms. The hair care composition also includes a non-aqueous volatile solvent. | 2021-12-16 |
20210386637 | TOPICAL COMPOSITION COMPRISING A LIQUID UVB-FILTER OIL - The present invention relates to isopropylparabene free topical compositions comprising a specific polyester and at least one liquid UVB-filter oil. Furthermore, the present invention relates to the use of such polyesters to reduce the transfer of oils to surfaces as well as to lessen the overall stickiness of such compositions. | 2021-12-16 |
20210386638 | SHAVE-CLEANSER COMPOSITION - Provided are skincare compositions that include a bactericide, one or more surfactants, water, and optionally saturated fatty acid. The composition may include a bactericide, surfactants (e.g., anionic and/or zwitterionic), saturated fatty acid, and no more than about 50 wt % water. Alternatively, the composition may include a bactericide, surfactants (e.g., anionic and/or nonionic), and at least about 50 wt % water. Commonly, the skincare compositions may include benzoyl peroxide and goat milk. The compositions may be used for various applications including cleaning the skin and as a shaving cream. | 2021-12-16 |
20210386639 | Foaming Topical Antimicrobial Cleaning Compositions - Provided are largely aqueous topical antimicrobial cleaning composition which provides an antimicrobial benefit, as well as methods for their production and methods for their use. The compositions comprise at least two different cationic surfactants which provide a primary antimicrobial benefit, and as a predominant further surfactant an amine oxide surfactant. The composition are at an acidic pH and are highly effective in providing an antimicrobial benefit to topical surfaces, e.g, epidermis and hair. | 2021-12-16 |
20210386640 | DISINFECTING COMPOSITION FOR TOPICAL USE - Disclosed is a disinfecting composition for topical use, including a surfactant mixture based on cocoyl glutamate and alkyl polyglycosides, at least one thickening and/or gelling agent, and at least one disinfectant. | 2021-12-16 |
20210386641 | METHYLENE BIS-BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL FOR FABRIC STAINING REDUCTION - The present invention relates to the use of methylene bis-benzotriazolyl tetramethylbutylphenol, optionally in combination with tris-biphenyl triazine, to reduce fabric staining of a sunscreen or daily care composition, wherein the sunscreen or daily care composition comprises (i) at least one particulate UV-f liter; and/or (ii) at least one oil soluble UV-A filter, wherein the at least one oil soluble UV-A filter is present in an amount of at most 3% by weight, based on the total weight of the sunscreen or daily care composition; and/or (iii) at least one water soluble UV filter. Furthermore, the present invention relates to the use of methylene bis-benzotriazolyl tetramethylbutylphenol, optionally in combination with tris-biphenyl triazine, to facilitate the washability of such sunscreen or daily care compositions from textiles. | 2021-12-16 |
20210386642 | SUNSCREEN COMPOSITIONS COMPRISING DROMETRIZOLE TRISILOXANE TO REDUCE FABRIC STAINING - The present invention relates to the use of drometrizole trisiloxane to reduce fabric staining of sunscreen compositions. Furthermore, the present invention relates to the use of drometrizole trisiloxane to facilitate the washability of sunscreen compositions from textiles. Furthermore, the present invention relates to a sunscreen composition comprising inter alia drometrizole trisiloxane. | 2021-12-16 |
20210386643 | EFFECTIVE TEETH WHITENING COMPOSITION UTILIZING BROMELAIN ENZYMES - The present invention embodies an effective teeth whitening composition that utilizes bromelain enzymes as the primary active ingredient and the main source of whitening. Further, the invention is a method for preparing the effective teeth whitening composition. The composition of an effective teeth whitener includes a sugar alcohol, calcium carbonate, a binder, an anionic detergent, a fluoride agent, sodium benzoate, and bromelain. | 2021-12-16 |
20210386644 | METHOD OF ASSESSING AND TREATING CELLULITE - The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient. | 2021-12-16 |
20210386645 | TOPICAL COMPOSITIONS - The present invention is concerned with the use of a PEG-emulsifier, optionally in combination with hyaluronic acid or a salt thereof for suppressing discoloration in topical compositions comprising vitamin B6 or a derivative thereof. Furthermore, the invention relates to a method for reducing discoloration of topical compositions containing vitamin B6 or a derivative thereof, comprising preparing a topical composition comprising vitamin B6, a PEG-emulsifiers and optionally hyaluronic acid and a cosmetically acceptable carrier. | 2021-12-16 |
20210386646 | TOPICAL COMPOSITIONS AND METHODS - The present invention relates generally to methods of use and compositions useful to reduce dark spots, age spots, and/or unwanted pigmentation of skin. The composition includes a combination of niacinamide, phytic acid, | 2021-12-16 |
20210386647 | NEW POLYOL POLYRHAMNOSIDES, PROCESS FOR THE PREPARATION THEREOF, AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING SAME - Disclosed is a composition based on a polyol of formula: HO—CH | 2021-12-16 |
20210386648 | SPRAY TYPE COSMETIC COMPOSITION HAVING MAKEUP-MAINTAINING ABILITY AND SPRAYING POWER - This disclosure provides a spray type cosmetic composition comprising hydroxypropyl starch (HPS) and polyvinylpyrrolidone (PVP). In more detail, this disclosure provides a spray-type cosmetic composition for makeup fixer, comprising HPS and PVP, which has excellent properties such as makeup maintaining ability, spraying power, and less stickiness at the same time. | 2021-12-16 |
20210386649 | USE OF SPECIFIC POLYMERS TO BRING ABOUT AN ANTI-POLLUTION EFFECT - The present invention relates to the use of a polymer or of a cosmetic product comprising said polymer, and additionally other known cosmetic ingredients, to bring about an anti-pollution effect on human skin or on human hair, especially to protect human skin or human hair from dust, wherein the polymer is a cationic, anionic or non-ionic polymer, and wherein the polymer has a solubility in water of at least 0.01 g of polymer in 100 g of water at 20° C. at least at a pH in the range between 4 and 9. | 2021-12-16 |
20210386650 | METHOD FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING AT LEAST ONE CATIONIC ACRYLIC COPOLYMER AND AT LEAST ONE PIGMENT - A method for treating human keratin fibers such as the hair is described and comprises the application to the keratin fibers of a dye composition comprising at least one cationic acrylic copolymer and at least one pigment, and the application to the dyed keratin fibers of a makeup-removing composition comprising at least one hydrocarbon oil. | 2021-12-16 |
20210386651 | METHOD OF DESIGNING FILM-FORMING AGENT OR COSMETIC CONTAINING THE SAME - A method of designing a film-forming agent for cosmetics, which can form a film having excellent water resistance and excellent sebum resistance while also having high washability, is provided. The method is also useful for designing a cosmetic containing the film-forming agent. The film-forming agent comprises a copolymer, which is formed by polymerizing a monomer composition. The monomer composition comprises: (A) an unsaturated monomer having at least one polysiloxane structure in the molecule; and (B) an unsaturated monomer having at least one acidic group or salt thereof in the molecule; wherein monomer (A) is present in an amount of at least 30 wt % relative to the weight of to the monomer composition. | 2021-12-16 |
20210386652 | OIL-IN-WATER EMULSION COSMETIC - The purpose of the present invention is to provide an oil-in-water emulsion cosmetic that is thickened using an associative thickener containing a hydrophobic modified polyether urethane, that stably holds a hydrophobization powder in an inner oil phase, and that does not release water even after long-term storage, without a reduction in usage sensations regarding moistness, resilience, and smoothness originally possessed by the oil-in-water emulsion cosmetic. The present invention is an oil-in-water emulsion cosmetic characterized by comprising (A) a hydrophobic modified polyether urethane having a specific structure such as polyurethane-59, (B) a polyether modified silicone having an HLB (Si) of 5-14, and (C) a hydrophobization powder. The cosmetic according to the present invention preferably further comprises (D) a lower alcohol and/or a polyol, and/or (E) a nonionic surfactant having an HLB of 8-18. The hydrophobization powder (C) is preferably a metal oxide powder treated with triethoxycaprylylsilane, dimethicone, hydrogen dimethicone, or a metallic soap. | 2021-12-16 |
20210386653 | COSMETIC TENSIONING COMPOSITION - The present application relates to cosmetic compositions and in particular, to skintightening compositions and to compositions that improve the appearance of the skin by providing skin-tightening improvements to the skin, for treatment of, for example, eye bags, facial wrinkles and other skin imperfections, the cosmetic compositions comprising a polyvalent silicate; at least one film former, and a carboxylic acid wherein the pH of the composition is in the range 6.0 to 11.2 wherein the composition provides a tightening effect on application to the skin. The present invention provides a composition which provides an efficient tightening product yet with good natural skin shine but without the white residue appearance associated with known products. | 2021-12-16 |
20210386654 | ANHYDROUS COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALS - It relates to an anhydrous composition for caring for and/or making up keratin materials comprising, a) 10%˜40% by weight of at least one non-volatile non-phenyl silicone oil, relative to the total weight of the composition; b) at least one non-volatile hydrocarbon-based oil and/or phenyl silicone oil; c) at least one high viscosity ester; and d) reaction product of an unsaturated-functional silicone resin, an Si—H functional organopolysiloxane crosslinker bearing pendant hydrido functionality and optionally, an unsaturated hydrocarbon having four or more carbon atoms, in a low viscosity organopolysiloxane. It relates to a process for caring for and/or making up keratin materials such as the skin and the lips, preferably the lips, by applying the anhydrous composition according to the present invention to the keratin materials. | 2021-12-16 |
20210386655 | HAIR COSMETIC AND HAIR TREATMENT METHOD USING SAME - The purpose of the present invention is to provide an aqueous hair cosmetic which contains a lower alcohol such as ethanol and water and is used by spraying in the form of a mist, wherein the hair cosmetic imparts a desired shape, smoothness, and water repellency to hair and has excellent retention of these effects. The present invention relates to a hair cosmetic characterized by containing: (A) a copolymer including a polysiloxane structure and a polyoxyalkylene structure in a main chain, and a side chain having a trialkoxysilane group or a silanol group; (B) a cationic surfactant; (C) a lower alcohol; and (D) water, and a hair treatment method using the same. | 2021-12-16 |
20210386656 | LINKABLE POLYSILOXANES IN COSMETIC PRODUCTS - The present disclosure provides a linkable cosmetic composition. The composition includes a vinyl pendant siloxane component and a hydrogen pendant siloxane component. The composition further includes a catalyst and a solvent. | 2021-12-16 |
20210386657 | HAIR TREATMENT COMPOSITION - The present invention is in the field of rinse-off conditioner compositions; in particular, relates to rinse-off conditioner compositions with improved conditioning benefits. Silicones are a commonly used conditioning agent and thus improved deposition of silicones is always desired. It is therefore an object of the present invention to provide improved silicone deposition and also improved sensory of hair. It has been found that the above objects can be achieved by a conditioner composition comprising a specific combination of silicones. | 2021-12-16 |
20210386658 | COSMETIC COMPOSITION - Methods of use and compositions useful for moisturizing skin, conditioning skin, reducing lines and wrinkles, evening skin tone, lightening skin tone, increasing skin radiance, elasticity, skin barrier function, and/or skin firmness, reducing photodamage, reducing sagging skin, increasing anti-oxidant capacity in skin, MMP-1, MMP-3, MMP-9, pro-inflammatory cytokines (e.g., lipoxygenase, IL-6, Il-8, TNF-α, or VEGF), and/or elastase expression in skin, and/or increasing collagen expression in skin, elastin expression in skin, laminin expression in skin, and/or fibronectin expression in skin are disclosed herein. The composition includes a combination of one or more of Rosmarinus officianalis leaf extract, Caulerpa lentillifera extract, Moms alba fruit extract, and Porphyridium cruentum extract. | 2021-12-16 |
20210386659 | MUCOADHESIVE DEVICES FOR THE RELEASE OF PROBIOTICS AND FOR THE MAINTENANCE OF THEIR ENZYME ACTIVITIES - The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities. | 2021-12-16 |
20210386660 | ORAL DISPERSIBLE VACCINE COMPRISING VIROSOMES - The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability. | 2021-12-16 |
20210386661 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS - Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye. | 2021-12-16 |
20210386662 | SNUFF COMPOSITION - Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity. | 2021-12-16 |
20210386663 | METHOD FOR TREATING OR MITIGATING PARKINSON'S DISEASE USING NICOTINE INHALER OR NICOTINE NASAL SPRAY - A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided. | 2021-12-16 |
20210386664 | Surfactant Formulations for Inhalation - The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and/or polypeptide and that are formulated for delivery to the pulmonary system via inhalation. | 2021-12-16 |
20210386665 | INHALATION POWDER MEDICINE, EVALUATION METHOD THEREOF, AND USE THEREOF - As an inhalation powder medicine excellent in dispersibility, pulmonary delivery, and deposition, there is provided an inhalation powder medicine, containing: an active ingredient in at least a part of the porous hollow spherical particles that are capable of being dispersed and crushed into smaller particles by inspiration and capable of swelling when the porous hollow spherical particles absorb moisture, wherein the smaller particles are also capable of swelling when the smaller particles absorb moisture. | 2021-12-16 |
20210386666 | INHALABLE POWDER FORMULATIONS OF ALGINATE OLIGOMERS - A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation. | 2021-12-16 |
20210386667 | NOVEL PREVENTIVE AND THERAPEUTIC TREATMENT FOR COVID 19 AND ANY OTHER DISEASE CAUSED BY SARS COV 2 - Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early stages of COVID 19, the pandemic disease caused by SARS CoV 2. These treatments are based on the administration the nasal cavity and/or the lungs of solutions containing iota Carrageenan with or without the addition of xylitol as antiviral drug substances. | 2021-12-16 |
20210386668 | Cyclodextrin for use in the treatment and prevention of late phase bronchoconstriction in allergen-induced asthma - An inhalable cyclodextrin for use in the treatment and prevention of late phase bronchoconstriction in allergen-induced asthma is disclosed. Further disclosed is the use of a cyclodextrin in the treatment and prevention by inhalation of late phase bronchoconstriction in allergen-induced asthma. | 2021-12-16 |
20210386669 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE - The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament. | 2021-12-16 |
20210386670 | NANOEMULSION SYSTEM FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL COMPOSITIONS AND OTHER ACTIVE AGENTS - A nanoemulsion system for transdermal delivery of a pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes a first phase, a second phase, and a third phase, and at least one pharmaceutical composition or other active agent. The first phase comprises an oil phase, the second phase comprises an aqueous phase, and the third phase comprises a final phase including a preservation agent. A method of preparing a nanoemulsion system for transdermal delivery of at least one pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes preparing predetermined amounts of first, second and third phases, heating and combining the first and second phases while stirring, cooling the initial mixture prior to adding the third phase, and cooling the resultant mixture to a final temperature while stirring to form the nanoemulsion system. | 2021-12-16 |
20210386671 | OPHTHALMIC FORMULATIONS PROVIDING DURABLE OCULAR LUBRICATION - This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations. | 2021-12-16 |
20210386672 | Oral Rapamycin Nanoparticle Preparations and Use - Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc. | 2021-12-16 |
20210386673 | OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF - Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time. | 2021-12-16 |
20210386674 | MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITOR - The present invention relates to modified release tablet formulations for oral administration of phosphodiesterase inhibitors. The pharmaceutical formulations are useful in the treatment, prevention or alleviation of dermal diseases or conditions. | 2021-12-16 |
20210386675 | METHOD FOR PRODUCT TRACKING IN AN INSTALLATION - A method for tracking product in an installation in which powdered product is processed into manufactured items is provided. The method comprises introducing the powdered product into the installation through at least one inlet, obtaining measurement data for the powdered product from at least one mass sensor positioned in the at least one inlet, and dividing the measurement data into mass units of equal size. The progression of the mass units is then tracked through the installation using measurement data from at least one other mass sensor in the installation. | 2021-12-16 |
20210386676 | METHOD OF CHEMICAL TAGGING OF TABLETS USING THE COATING - A method of chemically tagging tablet coatings and readout of the tag includes addition of the specific mass of the tagging substance to the coating and preparation of coatings with the tagging substance. The method additionally includes extraction of the compounds present in the tablet coating and chromatographic analysis of the compounds present in the coating. Further, the method includes comparison of the absolute, non-unitary concentration values and paraben mass to authenticate the results. | 2021-12-16 |
20210386677 | DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME - The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same. | 2021-12-16 |
20210386678 | BIOPOLYMER-ENCAPSULATED GLYCOSYL TRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS - Biopolymer-Encapsulated Glycosyltransferase Inhibitor Compositions and Methods for Treating Diabetes and Cardiac Indications. | 2021-12-16 |
20210386679 | ARTIFICIAL TEARS - The invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising: (i) a solid outer shell comprising a solid lipid, wherein the solid lipid comprises cholesterol; and (ii) a liquid core comprising a liquid lipid, wherein the liquid lipid comprises triglyceride; and related compositions, eye drop dispensers, uses and methods of treatment or prevention of a dry eye disorder in a subject. | 2021-12-16 |
20210386680 | SELECTIVELY CLEAVABLE THERAPEUTIC NANOPARTICLES - Disclosed herein are nanoparticles for therapeutic and diagnostic use. The nanoparticles are designed to selectively accumulate in a tissue or organ of interest, and then release one or more therapeutically active or diagnostic agents. The nanoparticles include self-crosslinked therapeutic agents and therapeutic agents dispersed in a matrix. | 2021-12-16 |
20210386681 | AMMONIA PAD WITH RELEASABLE SEAL - A flexible ammonia pad configured for mounting on the skin of an individual and for sealing and releasing an ammonia inhalant is provided. The pad includes a first flexible impermeable layer having bottom and top surfaces, an adhesive applied to the bottom surface, an ammonia mixture applied to the top surface, and a second flexible impermeable layer covering the top surface. The second layer has at least one outer edge sealed to the first layer and configured to releasably seal the ammonia mixture between the first and second layers. Preferably the ammonia mixture contains 2-15% of ammonia. | 2021-12-16 |
20210386682 | Method for supporting memory function and/or cognitive function - The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof | 2021-12-16 |
20210386683 | COMPOSITIONS AND METHODS RELATING TO RESVERATROL - The present invention relates to compositions and methods comprising resveratrol and uses thereof in the treatment of Alzheimer's disease, traumatic brain injury, and the brain associated pathologies associated therewith. The methods provide for the use of transmucosal delivery formulations that provide enhanced bioavailability of resveratrol in phamacologically active levels to a subject. The formulations are employed in treatment methods that include a regimen of one to several daily dosages of the formulation. The formulation includes resveratrol and a solubilizer in a defined weight ratio. Particular embodiments include transmucosal delivery of resveratrol from the composition. Methods for treating/inhibiting the symptoms associated with Alzheimer's disease and traumatic brain injury, employing the pharmaceutical compositions, in a subject, such as a human, are described. | 2021-12-16 |
20210386684 | DEVICE AND METHOD FOR TRANSDERMAL DELIVERY OF CANNADIBIOL - Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In reservoir patch designs, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In either design, the CBD may be provided as a pure compound or as a component of a | 2021-12-16 |
20210386685 | DEVICE AND METHOD FOR TRANSDERMAL DELIVERY OF CANNADIBIOL - Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In reservoir patch designs, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In either design, the CBD may be provided as a pure compound or as a component of a | 2021-12-16 |
20210386686 | Compositions Comprising Guaifenesin and Flavour Compounds Containing an Isovanillyl Group - The present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group. In particular, the present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of guaifenesin and one or more flavour compounds containing an isovanillyl group for the preparation of a pharmaceutical composition. Finally, the present invention relates to the use of one or more flavour compound(s) containing an isovanillyl group for masking or inhibiting the bitter taste of guaifenesin or of guaifenesin comprising compositions. | 2021-12-16 |
20210386687 | IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME - The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition. | 2021-12-16 |
20210386688 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION - The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression. | 2021-12-16 |
20210386689 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS - Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions. | 2021-12-16 |
20210386690 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME - Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 2021-12-16 |
20210386691 | Oral Dosage Forms of Ketamine - The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day. | 2021-12-16 |
20210386692 | NUTRITIONAL SUPPLEMENT CONTAINING L-a-GLYCEROPHOSPHORYLCHOLINE - A nutritional supplement contains 50% to 80% by weight of trimethylglycine; 5% to 30% by weight of L-α-glycerophosphorylcholine; 5% to 15% by weight of caffeine; and 5% to 10% by weight of an ingredient selected from the group consisting of an L-amino acid, creatyl-L-leucine, Corynanthe | 2021-12-16 |
20210386693 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID - The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease | 2021-12-16 |
20210386694 | DOSAGE REGIME - The present disclosure relates to use of cysteamine, formulations comprising cysteamine and pharmaceutically acceptable salts of cysteamine in the treatment of cystic fibrosis and conditions associated with cystic fibrosis. | 2021-12-16 |
20210386695 | Use Of Disulfiram For Treating Infection Of SARS-COV-2 - The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (M | 2021-12-16 |
20210386696 | NOVEL PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition for renal protection in chronic kidney disease, which contains a citric acid, a pharmaceutically acceptable salt of a citric acid, or a hydrate thereof; and a mixture of the citric acid, the pharmaceutically acceptable salt of the citric acid, and the hydrate thereof, and is a tablet. | 2021-12-16 |
20210386697 | PERAMIVIR SOLUTION TYPE INHALANT AND PREPARATION METHOD THEREFOR - Disclosed are a peramivir solution inhalant and a preparation method thereof, the solution inhalant includes: peramivir, an osmotic pressure regulator, a pH regulator, and water, wherein concentration of peramivir is greater than 15 mg/ml; concentration of the osmotic pressure regulator is less than 8 mg/ml; pH value of the solution inhalant ranges from 5.0 to 6.0; the peramivir solution is sterilized in a non-heating manner; the osmotic pressure regulator is selected from sodium chloride or glucose. The solution inhalant has a better stability and a good pulmonary targeting effect, which significantly improves pharmaceutical efficacy and safety. | 2021-12-16 |
20210386698 | Compositions and Methods for Preventing or Treating Diseases or Disorders Associated with Protein Misfolding - Methods and uses are disclosed herein. A method of treating a disease or disorder associated with improper protein folding within one or more of a subject's cells may include administering an effective amount of a treatment compound into the subject. The treatment compound includes buthionine sulfoximine. The treatment compound provides improved redox conditions to enhance the unfolded protein response and the degradation of protein aggregation. The buthionine sulfoximine may decrease cellular glutathione to achieve the desired oxidative milieu, but not to the extent where cellular toxicity occurs. | 2021-12-16 |
20210386699 | LIQUID READY-TO-USE FORMULATION OF LEVOTHYROXINE - The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability. | 2021-12-16 |
20210386700 | THERAPEUTIC COMPOSITIONS OF UNDECYLENIC ACID AND ARGININE - Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine. | 2021-12-16 |
20210386701 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE - In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. | 2021-12-16 |
20210386702 | METHOD FOR INHIBITING VIRUS INFECTION AND REPLICATION - Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. | 2021-12-16 |
20210386703 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS - Provided herein are devices, systems, kits and methods for treating skin conditions, ailments or diseases, such as skin warts. In some examples, a device for treating warts comprises a reservoir that includes a cantharidin formulation, and an applicator device in fluid communication with the reservoir that delivers the cantharidin formulation to a subject. | 2021-12-16 |
20210386704 | MDMA RESPONSE PREDICTION - A method of dosing an empathogen/entactogen in treating patients, by assessing patient characteristics before empathogen/entactogen use, administering empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of determining a dose of an empathogen/entactogen based on body weight, sex, and CYP2D6 activity by assessing patient characteristics of body weight, sex, and CYP2D6 activity before empathogen/entactogen use, administering the empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of refining dosing of an empathogen/entactogen. A method of predicting future dosing with an empathogen/entactogen. A method of evaluating feasibility of patients to receive an empathogen/entactogen as treatment. A method of optimizing empathogen/entactogen treatment in a patient. | 2021-12-16 |
20210386705 | APPLICATION OF CHIGLITAZAR AND RELATED COMPOUNDS THEREOF - Provided is an application of chiglitazar and related compounds thereof; in vitro models and animal models illustrate that chiglitazar and related compounds thereof inhibit fibroblast activation, matrix production, monocyte activation and chemotactic activity in vitro, and reduce inflammatory activity and tissue fibrosis area in animal models of liver fibrosis. Compared with known similar compounds, sodium chiglitazar shows more significant and different activity characteristics, and has better application potential for treating fibrotic disease. | 2021-12-16 |
20210386706 | METHODS FOR THE TREATMENT OF SCLERODERMA - The present invention relates to, inter alia, methods of treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) for scleroderma in an individual in need thereof. | 2021-12-16 |